Phase II data shows ABT 450/r, ABT 267, ABT 333 (Abbvie) successful in patients with Hepatitis C

New data from AbbVie's Phase IIb Aviator trial of ABT 450/r (protease inhibitor and ritonavir), ABT 267 (NS5A inhibitor) and ABT 333 (non-nucleoside polymerase inhibitor) for the treatment of Hepatitis C virus (HCV) infection demonstrates sustained viral response rates across multiple patient types with HCV Genotype 1. Data shows that 96 percent of treatment-naive patients and 93 percent of prior null responders treated with AbbVie's investigational IFN-free, triple-DAA combination therapy achieve SVR24.

In addition, similar high SVR rates observed after 12 and 24 weeks of treatment in the Phase IIb trial reinforce the adequacy of the 12-week treatment duration for the investigational interferon-free, triple DAA combination. Results will be presented at the 2013 International Liver Congress.